       Document 0008
 DOCN  M9550008
 TI    Constitutive production of nonenveloped human immunodeficiency virus
       type 1 particles by a mammalian cell line and effects of a protease
       inhibitor on particle maturation.
 DT    9505
 AU    Babe LM; Craik CS; Department of Pharmaceutical Chemistry, University of
       California,; San Francisco 94143-0446.
 SO    Antimicrob Agents Chemother. 1994 Oct;38(10):2430-9. Unique Identifier :
       AIDSLINE MED/95142590
 AB    A stable cell line encoding the sequences of all the human
       immunodeficiency virus type 1 proteins, with the exception of the gp160
       envelope glycoprotein, was derived from transfection of monkey COS-7
       cells. This cell line, referred to as CH-1, produces active viral
       protease that correctly processes its natural substrates and yields
       capsid particles. These particles contain reverse transcriptase activity
       and packaged viral RNA but are noninfectious. The level of expression of
       viral proteins is not toxic to the cells, yet it is comparable to that
       observed for chronically infected lymphocytes. These constitutively
       synthesized viral proteins provide a consistent system for the analysis
       of potential inhibitors of late viral functions. The lack of gp160
       increases the biosafety of this assay system, while it allows the
       measurement of the effects on the production and release of capsid
       particles. A human immunodeficiency virus type 1 protease inhibitor was
       used to confirm the viral polyprotein maturation pathway in this system.
       Particles from cells treated with this protease inhibitor contain
       unprocessed p55gag precursor and have the same density as the mature
       particles. These immature particles contain viral RNA, but reverse
       transcriptase activity is significantly reduced. This cell line may
       serve to identify compounds that are able to affect viral assembly and
       maturation as well as to identify the interactions between the viral and
       cellular proteins involved in these essential processes.
 DE    Base Sequence  Capsid/CHEMISTRY  Cell Line  HIV Core Protein
       p24/ANALYSIS  HIV Protease/GENETICS  HIV Protease
       Inhibitors/*PHARMACOLOGY  HIV-1/DRUG EFFECTS/*PHYSIOLOGY/ULTRASTRUCTURE
       Molecular Sequence Data  Oligopeptides/*PHARMACOLOGY  RNA,
       Viral/METABOLISM  Support, Non-U.S. Gov't  Support, U.S. Gov't, P.H.S.
       Virus Replication  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

